177 related articles for article (PubMed ID: 7506655)
1. Plasminogen-activator inhibitor type 2 (PAI-2) is a spontaneously polymerising SERPIN. Biochemical characterisation of the recombinant intracellular and extracellular forms.
Mikus P; Urano T; Liljeström P; Ny T
Eur J Biochem; 1993 Dec; 218(3):1071-82. PubMed ID: 7506655
[TBL] [Abstract][Full Text] [Related]
2. Purification of active human plasminogen activator inhibitor 1 from Escherichia coli. Comparison with natural and recombinant forms purified from eucaryotic cells.
Lawrence D; Strandberg L; Grundström T; Ny T
Eur J Biochem; 1989 Dec; 186(3):523-33. PubMed ID: 2514093
[TBL] [Abstract][Full Text] [Related]
3. Intracellular polymerization of the serpin plasminogen activator inhibitor type 2.
Mikus P; Ny T
J Biol Chem; 1996 Apr; 271(17):10048-53. PubMed ID: 8626560
[TBL] [Abstract][Full Text] [Related]
4. Structure-function studies of the SERPIN plasminogen activator inhibitor type 1. Analysis of chimeric strained loop mutants.
Lawrence DA; Strandberg L; Ericson J; Ny T
J Biol Chem; 1990 Nov; 265(33):20293-301. PubMed ID: 1700786
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the binding of urokinase-type plasminogen activator (u-PA) to plasminogen, to plasminogen-activator inhibitor-1 and to the u-PA receptor.
Lijnen HR; De Cock F; Collen D
Eur J Biochem; 1994 Sep; 224(2):567-74. PubMed ID: 7925373
[TBL] [Abstract][Full Text] [Related]
6. Vitronectin governs the interaction between plasminogen activator inhibitor 1 and tissue-type plasminogen activator.
Keijer J; Ehrlich HJ; Linders M; Preissner KT; Pannekoek H
J Biol Chem; 1991 Jun; 266(16):10700-7. PubMed ID: 1709939
[TBL] [Abstract][Full Text] [Related]
7. Expression and characterization of recombinant porcine plasminogen activator inhibitor-1.
Bijnens AP; Knockaert I; Cousin E; Kruithof EK; Declerck PJ
Thromb Haemost; 1997 Feb; 77(2):350-6. PubMed ID: 9157595
[TBL] [Abstract][Full Text] [Related]
8. A substrate-like form of plasminogen-activator-inhibitor type 1. Conversions between different forms by sodium dodecyl sulphate.
Urano T; Strandberg L; Johansson LB; Ny T
Eur J Biochem; 1992 Nov; 209(3):985-92. PubMed ID: 1425706
[TBL] [Abstract][Full Text] [Related]
9. Renaturation, purification, and characterization of human plasminogen activator inhibitor type 2 (PAI-2) accumulated at high level in Escherichia coli.
Zhou A; Jiang X; Dou F; Zhu D; Xu X
J Biochem; 1997 May; 121(5):930-4. PubMed ID: 9192735
[TBL] [Abstract][Full Text] [Related]
10. Alteration of serpin specificity by a protein cofactor. Vitronectin endows plasminogen activator inhibitor 1 with thrombin inhibitory properties.
Ehrlich HJ; Gebbink RK; Keijer J; Linders M; Preissner KT; Pannekoek H
J Biol Chem; 1990 Aug; 265(22):13029-35. PubMed ID: 1695900
[TBL] [Abstract][Full Text] [Related]
11. Differential inhibition of soluble and cell surface receptor-bound single-chain urokinase by plasminogen activator inhibitor type 2. A potential regulatory mechanism.
Schwartz BS
J Biol Chem; 1994 Mar; 269(11):8319-23. PubMed ID: 7907591
[TBL] [Abstract][Full Text] [Related]
12. Purification of recombinant plasminogen activator inhibitor-1 in the active conformation by refolding from inclusion bodies.
Lee HJ; Im H
Protein Expr Purif; 2003 Sep; 31(1):99-107. PubMed ID: 12963346
[TBL] [Abstract][Full Text] [Related]
13. Purification and characterization of active and stable recombinant plasminogen-activator inhibitor accumulated at high levels in Escherichia coli.
Sancho E; Tonge DW; Hockney RC; Booth NA
Eur J Biochem; 1994 Aug; 224(1):125-34. PubMed ID: 8076633
[TBL] [Abstract][Full Text] [Related]
14. Introduction of an RRHR motif into chicken urokinase-type plasminogen activator (ch-uPA) confers sensitivity to plasminogen activator inhibitor (PAI)-1 and PAI-2 and allows ch-uPA-mediated extracellular matrix degradation to be controlled by PAI-1.
Sipley JD; Alexander DS; Testa JE; Quigley JP
Proc Natl Acad Sci U S A; 1997 Apr; 94(7):2933-8. PubMed ID: 9096324
[TBL] [Abstract][Full Text] [Related]
15. Interaction of single-chain urokinase and plasminogen activator inhibitor type 1.
Manchanda N; Schwartz BS
J Biol Chem; 1995 Aug; 270(34):20032-5. PubMed ID: 7544349
[TBL] [Abstract][Full Text] [Related]
16. Binding of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex to the endocytosis receptors alpha2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor.
Rodenburg KW; Kjoller L; Petersen HH; Andreasen PA
Biochem J; 1998 Jan; 329 ( Pt 1)(Pt 1):55-63. PubMed ID: 9405275
[TBL] [Abstract][Full Text] [Related]
17. Characterisation of the complex of plasminogen activator inhibitor type 1 with tissue-type plasminogen activator by mass spectrometry and size-exclusion chromatography.
Strömqvist M; Karlsson KE; Björquist P; Andersson JO; Byström M; Hansson L; Johansson T; Deinum J
Biochim Biophys Acta; 1996 Jun; 1295(1):103-9. PubMed ID: 8679667
[TBL] [Abstract][Full Text] [Related]
18. Polymerization of plasminogen activator inhibitor-1.
Zhou A; Faint R; Charlton P; Dafforn TR; Carrell RW; Lomas DA
J Biol Chem; 2001 Mar; 276(12):9115-22. PubMed ID: 11102455
[TBL] [Abstract][Full Text] [Related]
19. Conversion of plasminogen activator inhibitor-1 from inhibitor to substrate by point mutations in the reactive-site loop.
Audenaert AM; Knockaert I; Collen D; Declerck PJ
J Biol Chem; 1994 Jul; 269(30):19559-64. PubMed ID: 8034724
[TBL] [Abstract][Full Text] [Related]
20. Engineering plasminogen activator inhibitor 1 mutants with increased functional stability.
Lawrence DA; Olson ST; Palaniappan S; Ginsburg D
Biochemistry; 1994 Mar; 33(12):3643-8. PubMed ID: 8142362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
